48,466
edits
Difference between revisions of "Programmed cell death 1"
Jump to navigation
Jump to search
Programmed cell death 1 (view source)
Revision as of 17:51, 23 November 2016
, 17:51, 23 November 2016→IHC
(→IHC) |
|||
| (23 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Programmed cell death 1''', abbreviated '''PDCD1''' and '''PD1''',<ref name=omim600244>{{OMIM|600244}}</ref> is a protein (and gene) with an important role in immune system regulation and [[cancer]]. It is found on | '''Programmed cell death 1''', abbreviated '''PDCD1''' and '''PD1''',<ref name=omim600244>{{OMIM|600244}}</ref> is a protein (and gene) with an important role in immune system regulation and [[cancer]]. It is found on T lymphocytes. | ||
It is also known as '''CD279'''. | It is also known as '''CD279'''. | ||
| Line 8: | Line 8: | ||
Cytotoxic T cell function is regulated by receptor pairs found on the tumour and lymphocyte:<ref name=pmid22658126>{{Cite journal | last1 = Ribas | first1 = A. | title = Tumor immunotherapy directed at PD-1. | journal = N Engl J Med | volume = 366 | issue = 26 | pages = 2517-9 | month = Jun | year = 2012 | doi = 10.1056/NEJMe1205943 | PMID = 22658126 }}</ref> | Cytotoxic T cell function is regulated by receptor pairs found on the tumour and lymphocyte:<ref name=pmid22658126>{{Cite journal | last1 = Ribas | first1 = A. | title = Tumor immunotherapy directed at PD-1. | journal = N Engl J Med | volume = 366 | issue = 26 | pages = 2517-9 | month = Jun | year = 2012 | doi = 10.1056/NEJMe1205943 | PMID = 22658126 }}</ref> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
! | ! Function | ||
! Tumour cell | ! Tumour cell | ||
! T cell | ! T cell | ||
|- | |- | ||
| Antigen | | Antigen presentation | ||
| MHC | | MHC | ||
| TCR | | TCR | ||
|- | |- | ||
| | | Signal inhibition | ||
| | | PD-1 | ||
| PD-L1 (CD274), PD-L2 (CD273) | | [[PD-L1]] (CD274), PD-L2 (CD273) | ||
|} | |} | ||
| Line 24: | Line 24: | ||
*Pembrolizumab. | *Pembrolizumab. | ||
*Nivolumab. | *Nivolumab. | ||
*Atezolizumab. | |||
*Durvalumab. | |||
*Avelumab. | |||
Uncertain whether it binds PD-1: | |||
*Pidilizumab. | *Pidilizumab. | ||
==IHC== | |||
*There is no standard antibody. | |||
*Currently, each drug company has its own clone. Whether the antibodies are interchangeable is a subject of study. | |||
<center> | |||
{| class="wikitable sortable" | |||
!Clone | |||
!IHC platform | |||
!Associated drug | |||
!Testing required | |||
|- | |||
| 28-8 | |||
| Dako | |||
| Nivolumab<ref>{{Cite journal | last1 = Borghaei | first1 = H. | last2 = Paz-Ares | first2 = L. | last3 = Horn | first3 = L. | last4 = Spigel | first4 = DR. | last5 = Steins | first5 = M. | last6 = Ready | first6 = NE. | last7 = Chow | first7 = LQ. | last8 = Vokes | first8 = EE. | last9 = Felip | first9 = E. | title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | journal = N Engl J Med | volume = 373 | issue = 17 | pages = 1627-39 | month = Oct | year = 2015 | doi = 10.1056/NEJMoa1507643 | PMID = 26412456 }}</ref> | |||
| no testing for squamous carcinoma, pending further information for non-squamous | |||
|- | |||
| 22C3 | |||
| Dako | |||
| Pembrolizumab<ref>{{Cite journal | last1 = Garon | first1 = EB. | last2 = Rizvi | first2 = NA. | last3 = Hui | first3 = R. | last4 = Leighl | first4 = N. | last5 = Balmanoukian | first5 = AS. | last6 = Eder | first6 = JP. | last7 = Patnaik | first7 = A. | last8 = Aggarwal | first8 = C. | last9 = Gubens | first9 = M. | title = Pembrolizumab for the treatment of non-small-cell lung cancer. | journal = N Engl J Med | volume = 372 | issue = 21 | pages = 2018-28 | month = May | year = 2015 | doi = 10.1056/NEJMoa1501824 | PMID = 25891174 }}</ref> | |||
| testing required | |||
|- | |||
| SP142 | |||
| Ventana | |||
| Atezolizumab<ref name=pmid26970723>{{Cite journal | last1 = Fehrenbacher | first1 = L. | last2 = Spira | first2 = A. | last3 = Ballinger | first3 = M. | last4 = Kowanetz | first4 = M. | last5 = Vansteenkiste | first5 = J. | last6 = Mazieres | first6 = J. | last7 = Park | first7 = K. | last8 = Smith | first8 = D. | last9 = Artal-Cortes | first9 = A. | title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. | journal = Lancet | volume = 387 | issue = 10030 | pages = 1837-46 | month = Apr | year = 2016 | doi = 10.1016/S0140-6736(16)00587-0 | PMID = 26970723 }}</ref> | |||
| testing required | |||
|- | |||
| SP263 | |||
| Ventana | |||
| Durvalumab | |||
| testing likely required | |||
|} | |||
</center> | |||
==See also== | ==See also== | ||